文献速递神经核医学肿瘤 PET/CT

68Ga-Pentixafor PET/CT用于胶质瘤CXCR4受体在体显像及放化疗反应评估的初步结果

68 Ga-Pentixafor PET/CT for In Vivo Imaging of CXCR4 Receptors in Glioma Demonstrating a Potential for Response Assessment to Radiochemotherapy: Preliminary Results.
PubMed 文献 · Clin Nucl Med · 2024-02-01

本研究纳入19例多形性胶质母细胞瘤患者,分别于术前(n=9)或放化疗前后(n=10)行68Ga-Pentixafor PET/CT、增强MR及MR波谱。所有患者均见示踪剂摄取,术前组平均SUVmean与胆碱/NAA比值显著相关(P<0.005);放化疗后随访SUVmax与基线无显著差异,但进展患者随访SUVmax及T/B比值显著高于基线及稳定患者。

要点

  • 68Ga-Pentixafor PET/CT可在体显像胶质母细胞瘤CXCR4受体,全部19例均见摄取。
  • 术前组SUVmean与胆碱/NAA比值显著相关(P<0.005)。
  • 放化疗后进展患者随访SUVmax及T/B比值显著高于基线(P<0.05)。

核心结论

  • 68Ga-Pentixafor PET/CT可用于多形性胶质母细胞瘤CXCR4受体的在体显像。
  • 该技术在更大 cohort 验证后,可能对早期发现胶质母细胞瘤复发及治疗反应评估具有附加诊断价值。

研究设计与样本

  • 前瞻性初步研究,纳入19例多形性胶质母细胞瘤患者(12男7女),行68Ga-Pentixafor PET/CT、增强MR及MR波谱。
  • 术前组(I组,n=9)于手术前扫描并将PET结果与CXCR4受体密度相关。
  • 术后组(II组,n=10)于放化疗前后扫描,用于治疗反应评估。

主要发现

  • 全部19例均见68Ga-Pentixafor摄取。
  • I组平均SUVmax 4.5±1.6、SUVmean 0.60±0.26、SUVpeak 1.95±0.8、T/B 6.9±4.6。
  • I组SUVmean与胆碱/NAA比值显著相关(P<0.005);7/9例免疫组化示CXCR4受体阳性(强度3+;染色细胞>50.0%)。
  • II组基线平均SUVmax 4.6±2.1,放化疗后随访为4.4±1.6,两者无显著差异。
  • 6个月临床随访时4例稳定,其随访SUVmax 3.70±0.90、T/B 2.64±1.35,低于基线对应值4.40±2.8与2.91±0.93;6/10例进展,其平均SUVmax及T/B比值显著高于基线对应值(P<0.05),也高于稳定患者。

局限性

  • 原文结论指出该技术需在更大 cohort 中验证后,才可能对早期发现复发及治疗反应评估具有附加诊断价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to evaluate the diagnostic potential of 68 Ga-pentixafor PET/CT for in vivo CXCR4 receptors imaging in glioma and its possible role in response assessment to radiochemotherapy (R-CT). METHODS: Nineteen (12 men, 7 women) patients with glioblastoma multiforme (GBM) underwent 68 Ga-pentixafor PET/CT, contrast-enhanced MR, and MR spectroscopy. Patients were divided in to 2 groups, that is, group I was the presurgical (n = 9) group in which the scanning was done before surgery, and PET findings were correlated with CXCR4 receptors' density. The group II was the postsurgical (n = 10) group in which the scanning was done before and after R-CT and used for treatment response evaluation. The quantitative analysis of 68 Ga-pentixafor PET/CT evaluated the mean SUV max , SUV mean , SUV peak , and T/B values. MR spectroscopy data evaluated the ratios of tumor metabolites (choline, NAA, creatine). RESULTS: 68 Ga-Pentixafor uptake was noted in all (n = 19) the patients. In the group I, the mean SUV max , SUV mean , SUV peak , and T/B values were found to be 4.5 ± 1.6, 0.60 ± 0.26, 1.95 ± 0.8, and 6.9 ± 4.6, respectively. A significant correlation ( P < 0.005) was found between SUV mean and choline/NAA ratio. Immunohistochemistry performed in 7/9 showed CXCR4 receptors' positivity (intensity 3 + ; stained cells >50.0%). In the group II, the mean SUV max at baseline was 4.6 ± 2.1 and did not differ (4.4 ± 1.6) significantly from the value noted at post-R-CT follow-up PET/CT imaging. At 6 months' clinical follow-up, 4 patients showed stable disease. SUV max and T/B ratios at follow-up imaging were lower (3.70 ± 0.90, 2.64 ± 1.35) than the corresponding values (4.40 ± 2.8; 2.91 ± 0.93) noted at baseline. Six (6/10) patients showed disease progression, and the mean SUV max , and T/B ratio in these patients were significantly ( P < 0.05) higher than the corresponding values at baseline and also higher than that noted in the stable patients. CONCLUSIONS: 68 Ga-Pentixafor PET/CT can be used for in vivo mapping of CXCR4 receptors in GBM. The technique after validation in a large cohort of patients may have added diagnostic value for the early detection of GBM recurrence and for treatment response evaluation.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Waheed A, Singh B, Watts A, et al. 68 Ga-Pentixafor PET/CT for In Vivo Imaging of CXCR4 Receptors in Glioma Demonstrating a Potential for Response Assessment to Radiochemotherapy: Preliminary Results. Clin Nucl Med. 2024. PMID: 38350065. doi:10.1097/RLU.0000000000005073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。